LFMD - LifeMD, Inc.
NASDAQ
->
Healthcare
->
Pharmaceutical Retailers
New York,
United States
Type: Equity
LFMD price evolution
LFMD
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $33.15 | $15.29 | $11.91 | $11.52 |
| Short term investments | ||||
| Net receivables | $5.28 | $4.42 | $3.67 | $2.94 |
| Inventory | $2.76 | $3.79 | $3.7 | $3.38 |
| Total current assets | $42.6 | $24.89 | $20.18 | $19.16 |
| Long term investments | ||||
| Property, plant & equipment | $1.07 | $1.22 | $1.37 | $1.58 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $58.48 | $40.69 | $35.45 | $33.87 |
| Current liabilities | ||||
| Accounts payable | $11.08 | $9.64 | $9.59 | $6.9 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $34.78 | $32.52 | $31.52 | $27.02 |
| Long term debt | $17.93 | $18.83 | $13.54 | $13.42 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $54.98 | $53.36 | $46.44 | $41.2 |
| Shareholders' equity | ||||
| Retained earnings | -$214.27 | -$209.76 | -$202.86 | -$195.35 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $33.15 | $3.96 | $41.33 | $9.18 |
| Short term investments | ||||
| Net receivables | $5.28 | $2.83 | $0.98 | $0.65 |
| Inventory | $2.76 | $3.7 | $1.62 | $1.26 |
| Total current assets | $42.6 | $11.31 | $44.92 | $12.06 |
| Long term investments | ||||
| Property, plant & equipment | $1.07 | $1.68 | $1.99 | $0.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.99 | |||
| Total investments | ||||
| Total assets | $58.48 | $25.67 | $49.92 | $13.05 |
| Current liabilities | ||||
| Accounts payable | $11.08 | $10.11 | $9.06 | $11.79 |
| Deferred revenue | $0.92 | |||
| Short long term debt | ||||
| Total current liabilities | $34.78 | $31.37 | $22.83 | $13.49 |
| Long term debt | $17.93 | |||
| Total noncurrent liabilities | $0.39 | |||
| Total debt | ||||
| Total liabilities | $54.98 | $32.5 | $23.07 | $13.88 |
| Shareholders' equity | ||||
| Retained earnings | -$214.27 | -$190.56 | -$141.92 | -$80.15 |
| Other shareholder equity | -$2.34 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $30.46 | |||
| Cost of revenue | ||||
| Gross Profit | $25.82 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $38.73 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.13 | |||
| Net income | ||||
| Net income | -$13.02 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $37.29 | $12.47 | $8.32 | |
| Cost of revenue | ||||
| Gross Profit | $28.39 | $9.94 | $6.33 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $87.11 | $13.36 | $9.38 | |
| Operating income | -$57.82 | -$2.89 | -$2.06 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.12 | -$0.12 | -$0.12 | |
| Interest expense | $1.67 | $0.76 | $0.35 | |
| Net income | ||||
| Net income | -$58.65 | -$3.14 | -$1.24 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$12.13 | -$9.89 | -$7.38 | -$3.4 |
| Financing activities | ||||
| Dividends paid | -$2.33 | -$1.55 | -$0.78 | -$0.87 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$2.39 | -$1.53 | -$0.77 | $68.64 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$35.49 | -$29.61 | -$16.24 | $32.15 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Net income | -$60.52 | -$3.53 | -$1.36 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$12.13 | $0.25 | -$0.91 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$3.4 | -$0.8 | -$0.1 | $0.14 |
| Financing activities | ||||
| Dividends paid | -$0.87 | |||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $68.64 | $21 | $0.78 | $0.8 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $32.15 | $8.07 | $0.93 | $0.04 |
News
Fundamentals
| Market cap | $416.60M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 38.26M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.87 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.22 |
| Quick ratio | 1.15 |